Search for European Projects

12 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)

Start date: Jan 1, 2015, End date: Dec 31, 2021,

Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Read Project

 44

 FINISHED 

Treatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neonates and infants aged under three months (NEOVANC)

Start date: Feb 1, 2014, End date: Jan 31, 2019,

Vancomycin is the critically important antibiotic to treat neonatal Late Onset Sepsis (LOS) due to Gram positive bacteria in neonates, including Coagulase Negative Staphylococci (CoNS) and Staphylococcus aureus. These organisms also create biofilms which are extremely resistant to antibiotics. The increased incidence of LOS due to bacteria such as CoNS and MRSA in NICUs has led to a marked increas ...
Read Project

 14

 FINISHED 

Systems medicine of chronic inflammatory bowel disease (SYSMEDIBD)

Start date: Dec 1, 2012, End date: Nov 30, 2017,

Inflammatory bowel disease (IBD) is a major health problem with severe co-morbidities, requiring life-long treatment. Oscillating processes, like biological clocks are well studied and modeled in a number of systems. Circadian rhythms are extremely important for optimal treatments of patients. Recently, the NfkB pathway has been shown to be oscillating. In this project, we will model NfkB oscillat ...
Read Project

 13

 FINISHED 

Preserving old antibiotics for the future : assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics (AIDA)

Start date: Dec 1, 2011, End date: Nov 30, 2017,

The AIDA project aims to answer the question of clinical effectiveness and optimal dosing of 5 off-patent antibiotics for infections caused by multiple drug resistant (MDR) bacteria in three randomized controlled clinical trials. In an era of increasing emergence of drug resistance (EDR) and lack of new antibiotics, old off- patent antibiotics are increasingly being prescribed to patients. However ...
Read Project

 19

 FINISHED 

Model-based preclinical development of anti-tuberculosis drug combinations (PREDICT-TB)

Start date: May 1, 2012, End date: Oct 30, 2017,

Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical sy ...
Read Project

 23

 FINISHED 

Recognising Adverse Drug Reactions (WEB-RADR)

Start date: Sep 1, 2014, End date: Aug 31, 2017,

WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Read Project

 20

 FINISHED 

Metformin for treatment of polycystic ovary syndrome in children (METFIZZ)

Start date: Oct 1, 2013, End date: Mar 31, 2017,

PCOS, a common disorder affecting 5-10% of women of reproductive age is characterized by cystic ovarian morphology, androgen excess, and/or irregular periods and emerges during or shortly after puberty. The common off-label use of metformin for treating PCOS in children appears to have no greater risk than that in adults; drug tolerance is good with limited adverse effects. However, clinical trial ...
Read Project

 7

 FINISHED 

Personalisation of tREatment In Cardiovascular disease through next generation sequencing in Adverse Drug Reactions (PREDICTION-ADR)

Start date: Sep 1, 2013, End date: Feb 28, 2017,

Prediction-ADR aims to discover the genetic factors predisposing patients to adverse drug reactions (ADRs) from cardiovascular disease (CVD) drugs. This will be achieved by assembling a consented blood bank and DNA for a population of ~500 cases of ACEi induced angioedema and statin induced myopathy defined using a standardised phenotypic criteria. An innovative next generation sequencing strategy ...
Read Project

 7

 FINISHED 

The potential of human kidney stem/progenitor cells for use in drug discovery and regenerative therapy programmes (NEPHROTOOLS)

Start date: Dec 1, 2011, End date: Nov 30, 2015,

Renal disease is a global public health problem, with the incidence of end stage renal disease (ESRD) rising annually. Current treatment options for ESRD are dialysis or renal transplantation, which have significant drawbacks in terms of increased morbidity and mortality, besides placing an increasing economic burden on society. The development of interventions aimed at preventing ESRD, including ...
Read Project

 11

 FINISHED 

Epilepsy Pharmacogenomics: delivering biomarkers for clinical use (EpiPGX)

Start date: Nov 1, 2011, End date: Oct 31, 2015,

The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs).The need for improved treatments in epilepsy is undoubted. Epilepsy is affects 50,000,000 people of all ages worldwide. Epilepsy is serio ...
Read Project

 15

 FINISHED 

Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)

Start date: Jan 1, 2011, End date: Dec 31, 2014,

Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Read Project

 11

 FINISHED 

International Data Exchange and Data Representation Standards for Proteomics (ProteomeXchange)

Start date: Jan 1, 2011, End date: Jun 30, 2014,

Over the last few years the field of proteomics has evolved into a prolific data producer. As a result, various databases that collect and redistribute the acquired data have been established. While data format standards for quantitative proteomics have now been defined and implemented with significant contribution from the recently completed EU ProDaC grant, standards for quantitative proteomics ...
Read Project

 13